Psychiatry's next top model: cause for a re-think on drug models of psychosis and other psychiatric disorders

被引:33
作者
Carhart-Harris, R. L. [1 ]
Brugger, S. [1 ]
Nutt, D. J. [1 ]
Stone, J. M. [1 ]
机构
[1] Univ London Imperial Coll Sci Technol & Med, Neuropsychopharmacol Unit, Div Expt Med, London W12 0NN, England
基金
英国医学研究理事会;
关键词
Model; pharmacology; psychosis; drugs; depression; alcohol; cannabis; psilocybin; ketamine; amphetamine; MYSTICAL-TYPE EXPERIENCES; NEGATIVE SYMPTOMS; SCHIZOPHRENIA; AMPHETAMINE; PSILOCYBIN; STATE;
D O I
10.1177/0269881113494107
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Despite the widespread application of drug modelling in psychiatric research, the relative value of different models has never been formally compared in the same analysis. Here we compared the effects of five drugs (cannabis, psilocybin, amphetamine, ketamine and alcohol) in relation to psychiatric symptoms in a two-part subjective analysis. In the first part, mental health professionals associated statements referring to specific experiences, for example I don't bother to get out of bed', to one or more psychiatric symptom clusters, for example depression and negative psychotic symptoms. This measured the specificity of an experience for a particular disorder. In the second part, individuals with personal experience with each of the above-listed drugs were asked how reliably each drug produced the experiences listed in part 1, both acutely and sub-acutely. Part 1 failed to find any experiences that were specific for negative or cognitive psychotic symptoms over depression. The best model of positive symptoms was psilocybin and the best models overall were the acute alcohol and amphetamine models of mania. These results challenge current assumptions about drug models and motivate further research on this understudied area.
引用
收藏
页码:771 / 778
页数:8
相关论文
共 40 条
[1]  
Atakan Z, 2012, PSYCHOL MED, P1
[2]   User perceptions of the benefits and harms of hallucinogenic drug use: A web-based questionnaire study [J].
Carhart-Harris, R. L. ;
Nutt, D. J. .
JOURNAL OF SUBSTANCE USE, 2010, 15 (04) :283-300
[3]   From drugs to deprivation: a Bayesian framework for understanding models of psychosis [J].
Corlett, P. R. ;
Frith, C. D. ;
Fletcher, P. C. .
PSYCHOPHARMACOLOGY, 2009, 206 (04) :515-530
[4]   Modelling psychosis [J].
Curran, H. Valerie ;
D'Souza, Deepak Cyril ;
Robbins, Trevor W. ;
Fletcher, Paul .
PSYCHOPHARMACOLOGY, 2009, 206 (04) :513-514
[5]   Delta-9-tetrahydrocannabinol effects in schizophrenia: Implications for cognition, psychosis, and addiction [J].
D'Souza, DC ;
Abi-Saab, WM ;
Madonick, S ;
Forselius-Bielen, K ;
Doersch, A ;
Braley, G ;
Gueorguieva, R ;
Cooper, TB ;
Krystal, JH .
BIOLOGICAL PSYCHIATRY, 2005, 57 (06) :594-608
[6]  
Di Forti M, 2005, EPIDEMIOL PSICHIAT S, V14, P184
[7]   The amphetamine-induced sensitized state as a model of schizophrenia [J].
Featherstone, R. E. ;
Kapur, S. ;
Fletcher, P. J. .
PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY, 2007, 31 (08) :1556-1571
[8]   Perceiving is believing: a Bayesian approach to explaining the positive symptoms of schizophrenia [J].
Fletcher, Paul C. ;
Frith, Chris D. .
NATURE REVIEWS NEUROSCIENCE, 2009, 10 (01) :48-58
[9]   Transients, metastability, and neuronal dynamics [J].
Friston, KJ .
NEUROIMAGE, 1997, 5 (02) :164-171
[10]   Psychological effects of (S)-ketamine and N,N-dimethyltryptamine (DMT): A double-blind, cross-over study in healthy volunteers [J].
Gouzoulis-Mayfrank, E ;
Heekeren, K ;
Neukirch, A ;
Stoll, M ;
Stock, C ;
Obradovic, M ;
Kovar, KA .
PHARMACOPSYCHIATRY, 2005, 38 (06) :301-311